Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GLPG4716 · GLP 4716, OAT 889

Other · developed by Lakefront Biotherapeutics NV

Phase 1 Most advanced trial (none active)
LKFT Developer
1 Registered trials

What is GLPG4716?

GLPG4716 is an investigational drug studied in Healthy.

At a glance

Also known as
GLP 4716, OAT 889
Drug type
Other
Developer
Lakefront Biotherapeutics NV (LKFT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
X4D0G881CN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04971746 Phase 1 Healthy Completed LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

More from Lakefront Biotherapeutics NV

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.

Follow LKFT, the company behind GLPG4716

See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LKFT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.